Disease relevance of HDAC10

• When the activated adherent cells were added to non-adherent cells or the cells from lymphoid cell line (HD-10), derived from Hodgkin's disease, DNA synthesis of these target cells was suppressed [1].

High impact information on HDAC10

• We find that VPA and its analogs inhibit multiple HDACs from class I and class II (but not HDAC6 or HDAC10) with a characteristic order of potency in vitro [2].
• Affinity isolation of protein serine/threonine phosphatases on the immobilized phosphatase inhibitor microcystin-LR identified histone deacetylase 1(HDAC1), HDAC6, and HDAC10 as novel components of cellular phosphatase complexes [3].
• In addition, based upon the public data base, a single nucleotide polymorphism was found in the C terminus of HDAC10 which changes a Gly residue to Cys, suggesting that HDAC10 molecules containing these single nucleotide polymorphisms may be folded improperly [4].
• The genomic structure of HDAC10 was found to consist of 20 exons [4].
• A novel histone deacetylase, HDAC10, was isolated from a mixed tissue human cDNA library [4].

Biological context of HDAC10

• Molecular cloning and Northern blot analyses reveal that the HDAC10 transcript is widely expressed and subjected to alternative splicing [5].
• Distinct from other family members, HDAC10 harbors an amino-terminal catalytic domain and a carboxyl pseudo-repeat that shares significant homology with its catalytic domain [5].

Associations of HDAC10 with chemical compounds

• The leucine-rich domain of HDAC10 is responsible for its cytoplasmic enrichment [6].
• Recombinant HDAC10 protein possesses histone deacetylase activity, which is sensitive to trichostatin A, a specific inhibitor for known class I and class II histone deacetylases [6].
• The HD10 trial tested four cycles of Adriamycin (doxorubicin), bleomycin, vinblastine, and dacarbazine (ABVD) against two cycles of ABVD followed by 20 Gy of IF-RT vs. 30 Gy of IF-RT (four study arms) [7].

Other interactions of HDAC10

• HDAC10 was classified as a class II subfamily member based upon similarity to HDAC6 [4].
• Randomized studies and most recently the GHSG HD 10 and HD 11 documented excellent results with low-dose IFRT of only 20 Gy in both early stage and in intermediate-stage patients [8].

Analytical, diagnostic and therapeutic context of HDAC10

• HDAC10 has two sequence variants, HDAC10v1 and HDAC10v2, and two transcripts were detectable by Northern blot analysis [4].
• The central prospective radiation oncological review of all diagnostic imaging showed that corrections of disease involvement in 49% of patients with early stages (HD10) and in 67% for patients with intermediate stages (HD11) were necessary [9].

References